Factors associated with extended treatment among tuberculosis patients at risk of relapse in California

被引:8
作者
Qin, F. [1 ]
Barry, P. M. [2 ]
Pascopella, L. [2 ]
机构
[1] Stanford Univ, Dept Med, Palo Alto, CA 94304 USA
[2] Calif Dept Publ Hlth, Ctr Infect Dis, Div Communicable Dis Control, TB Control Branch, 850 Marina Bay Pkwy, Richmond, CA 94804 USA
关键词
United States; guidelines; outcomes; health services; PULMONARY TUBERCULOSIS; ELIMINATION;
D O I
10.5588/ijtld.15.0469
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
SETTING: California, United States. OBJECTIVE: To determine the frequency of tuberculosis (TB) patients at risk for relapse who received at least 9 months of anti-tuberculosis treatment (extended treatment) and to identify factors associated with not receiving extended treatment. DESIGN: We analyzed characteristics of culture-confirmed pulmonary TB patients reported to the California TB Registry during 2004-2009. Patients with cavities on initial chest radiograph and delayed culture conversion ((>=. 70 days) were at 'high risk of relapse', and anti-tuberculosis treatment of >= 270 days was 'extended treatment'. We used a generalized linear model to identify independent risk factors for absence of extended treatment in the high risk of relapse group. RESULTS: Among 5680 TB patients, 483 (8.5%) were at high risk of relapse: 372 (77%) received extended treatment but 111 (23%) did not. Factors associated with absence of extended treatment included negative sputum smears (adjusted prevalence ratio [aPR] 2.62, 95%CI 1.69-4.05), residence in three specific counties (aPR 1.71, 95%CI 1.19-2.46) and Black race (aPR 1.56, 95 %CI 1.03-2.38). CONCLUSIONS: Nearly a quarter of TB patients at high risk of relapse did not receive extended treatment. Increased efforts are needed to ensure that all patients who may benefit from extended anti-tuberculosis treatment receive it.
引用
收藏
页码:363 / 369
页数:7
相关论文
共 22 条
[1]  
[Anonymous], 2014, Global strategy and targets for tuberculosis prevention, care and control after 2015
[2]  
Benator D, 2002, LANCET, V360, P528, DOI 10.1016/S0140-6736(02)09742-8
[3]  
Cass Anne, 2013, Public Health Rep, V128, P367, DOI 10.1177/003335491312800507
[4]  
Centers for Disease Control and Prevention, 2011, NAT DIAB FACT SHEET
[5]  
Centers for Disease Control and Prevention, 2014, MIN HLTH BLACK AFR A
[6]  
Centers for Disease Control and Prevention (CDC), 2003, MMWR Recomm Rep, V52, P1
[7]  
Centers for Disease Control and Prevention (CDC), 2013, REP TUB US 2012
[8]   A nested case-control study on treatment-related risk factors for early relapse of tuberculosis [J].
Chang, KC ;
Leung, CC ;
Yew, WW ;
Ho, SC ;
Tam, CM .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 170 (10) :1124-1130
[9]   Tuberculosis elimination: theory and practice in Europe [J].
D'Ambrosio, Lia ;
Dara, Masoud ;
Tadolin, Marina ;
Centis, Rosella ;
Sotgiu, Giovanni ;
van der Werf, Marieke J. ;
Gaga, Mina ;
Cirillo, Daniela ;
Spanevello, Antonio ;
Raviglione, Mario ;
Blasi, Francesco ;
Migliori, Giovanni Battista .
EUROPEAN RESPIRATORY JOURNAL, 2014, 43 (05) :1410-1420
[10]  
Driver CR, 2005, J PUBLIC HEALTH MAN, V11, P361